Vimarsana
Biggest News Aggregation in the World

Breakthrough Therapy Designations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Designations Today - Breaking & Trending Today

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting - Vimarsana News

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Published: June 2, 2024

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

Source: sina.com.hk
Related Topics:
Rhui ZhouUnited StatesHong KongSanofi IncyteEli LillyWei LiInnovent BiologicsCaicun ZhouChina National Medical Products AdministrationMd Anderson Cancer CenterDrug AdministrationNational Medical Products AdministrationInnovent Or CompanyDepartment Of Oncology At Shanghai East HospitalTongji UniversityInnovent Biologics IncAmerican Society Of Clinical OncologyClinical OncologyDrug EvaluationPrincipal InvestigatorShanghai East HospitalSenior Vice PresidentBreakthrough Therapy DesignationsPriority Review DesignationsNew Drug Applications
Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ... - Vimarsana News

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

Published: June 2, 2024

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Source: menafn.com
Related Topics:
Rhui ZhouHong KongUnited StatesEli LillyInnovent BiologicsCaicun ZhouSanofi IncyteWei LiDrug AdministrationNational Medical Products AdministrationDepartment Of Oncology At Shanghai East HospitalInnovent Or CompanyTongji UniversityChina National Medical Products AdministrationMd Anderson Cancer CenterAmerican Society Of Clinical OncologyPrnewswire Innovent Biologics IncInnovent Biologics IncClinical OncologyDrug EvaluationPrincipal InvestigatorShanghai East HospitalSenior Vice PresidentBreakthrough Therapy DesignationsPriority Review Designations
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting - Vimarsana News

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

Published: June 2, 2024

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in

Source: thailand-business-news.com
Related Topics:
United StatesYu WangVanesa GregorcRafael RosellChina National Medical Products AdministrationAmerican Society Of Clinical OncologyCandiolo Cancer InstituteGenfleet TherapeuticsClinical OncologyNational Medical Products AdministrationChief Medical OfficerPriority Review DesignationBreakthrough Therapy DesignationsThailand Business
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates - Vimarsana News

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

Published: May 24, 2024

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesYuxiang MaHaibo QiuMasa LasicaPrnewswire Ascentage PharmaHuafeng WangAscentage PharmaYifan ZhaiMd Anderson Cancer CenterAmerican Society Of Clinical OncologySun Yat Sen University Cancer CenterZhejiang University School Of MedicineMajor NationalDana Farber Cancer InstituteChina National Medical Products AdministrationNational Reimbursement Drug ListClinical OncologyAnnual MeetingOral ReportsChief Medical OfficerCentral TimeHematologic MalignanciesMyelodysplastic SyndromesFirst Affiliated Hospital
Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs - Vimarsana News

Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs

Published: May 23, 2024

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

Source: ibtimes.co.uk
Related Topics:
William BlairCathie WoodTony ColesDeutsche BankHc Wainwright CoWells FargoMorgan StanleyBarclays CapitalGoldman SachsArk InvestWall StreetArk Genomic RevolutionPrime MedicinePrime EditingPrime EditorIntegrated Drug CreationBreakthrough Therapy Designations